Report
Paul de Froment ...
  • Thomas Mordelle

Landmark contract in Europe

Nel has announced a new order from HH2E for 120MW of alkaline electrolysers with a value close to EUR34m. This is good news for the company, as it confirms previous LoI announcements, contracting expectations in H1 2023 and is one of the first-of-its-kind in Europe. Already with NOK505m in order in
Underlying
NEL ASA

NEL ASA develops diagnostic tests for early detection of diseases. Co.'s patented method is based on identifying disease-specific gene expression signatures from sample materials, such as blood. Co.'s products in development phase include MCItect, for patients with Mild Cognitive Impairment (MCI) aimed to detect Alzheimer disease within two years prior to onset of dementia, and ADtect, for the detection of mild to moderate Alzheimer disease, as well as one project in discovery phase, namely AMYtect, for brain amyloid detection.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Paul de Froment

Thomas Mordelle

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch